Researchers developed mAge, a biological aging framework that integrates plasma proteomics with wearable device data to predict biological age with unprecedented precision—achieving 0.87 test R² and just 2.3 years mean error in UK Biobank samples. The system reduces mortality prediction error by 21% compared to single-data approaches and creates organ-specific aging clocks across 49 biological subsystems, revealing cardiac, immune, and intracellular protein signatures benefit most from wearable integration. This represents a significant advance in aging measurement precision, moving beyond crude chronological age to capture biological reality across multiple physiological domains simultaneously. The framework's drug discovery component identified FDA-approved interventions like GLP-1 receptor agonists, gabapentin, and ACE inhibitors associated with lower proteomic age and reduced mortality risk. However, this preprint awaits peer review, and the observational nature means causality remains unproven. The integration of continuous digital monitoring with molecular diagnostics could enable personalized longevity interventions, though real-world validation and accessibility remain crucial hurdles. This appears paradigm-shifting for precision aging medicine if the methodology withstands rigorous peer review.